Introduction
Problems of resistance to extended-spectrum cephalosporins have been reported regularly since soon after the introduction of these antibiotics into clinical practice. Initially these were limited to nosocomial pathogens that carried an inducible, chromosomally located -lactamase gene of the AmpC type. 1 However, in the late 1980s, plasmid-mediated extended-spectrum -lactamases (ESBLs) emerged as an increasing threat to the continued use of this family of antibiotics. These arose by the accumulation of point mutations in the genes encoding penicillinases such as TEM-1 and SHV-1. 2 Highly mobile genes could then spread resistance to important therapeutic compounds. Standard in-vitro susceptibility testing often fails to detect clinically significant resistance. Of 35 European intensive therapy units, 23 reported Klebsiella spp. producing ESBLs. 3 A number of -lactamase genes, such as the BIL, CMY, LAT and MOX families, have been reported, which confer resistance to extended-spectrum cephalosporins and cephamycins and are unaffected by the presence of the -lactamase inhibitor clavulanic acid. The genes encoding these resistance determinants are located on plasmids but analysis of their nucleotide sequences shows that they are
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Transcontinental importation into the UK of Escherichia coli expressing a plasmid-mediated AmpC-type -lactamase exposed during an outbreak of SHV-5 extended-spectrum -lactamase in a Leeds hospital Sixteen strains of Escherichia coli with high-level resistance to extended-spectrum cephalosporins and other classes of antibiotic have been isolated at St James' University Hospital, Leeds. They produce up to three separate -lactamases: TEM-1, SHV-5 and, in five isolates, a plasmid-mediated AmpC-type enzyme. With the exception of carbapenems, the isolates reported in this study were resistant to all -lactam antibiotics including extendedspectrum cephalosporins and the monobactam aztreonam. There was evidence of the spread of a plasmid encoding SHV-5, particularly amongst patients on the liver transplant unit. Sensitivity to -lactam antibiotics in five isolates expressing the AmpC-type -lactamase was not restored by the -lactamase inhibitor clavulanic acid. These bacteria also carried bla SHV-5 on a large plasmid. PCR-amplification of the structural gene and digestion with restriction endonucleases demonstrated that the plasmid-mediated bla AmpC probably identified as BIL-1 using the criteria available. Four of the five patients carrying isolates that carried the plasmid-located bla AmpC gene had recently visited the Indian subcontinent and we presume that they returned carrying these bacteria. Restriction fragment length polymorphism analysis using pulsed field gel electrophoresis (PFGE) suggests that at least four distinct strains existed amongst these five isolates. The two isolates that had very similar PFGE patterns had different plasmid profiles and were isolated from different locations in the hospital and at different times. This study demonstrates the ease with which highly resistant bacteria can be imported into the UK and spread within hospitals. In the late 1980s, the Paediatric Oncology Unit at St James' University Hospital experienced a major problem associated with resistance to extended-spectrum cephalosporins caused by the evolution and dissemination of a family of TEM-derived -lactamases. 13 Surveillance for ESBLs in this hospital has continued over a period of 21 months on other wards, and the results are presented here.
Materials and methods

Bacterial strains
Sixteen isolates of Escherichia coli producing ESBL and expressing high level resistance to ESBL antibiotics were collected between February 1994 and November 1995 from patients at St James' University Hospital, Leeds. Of these isolates, ten were derived from patients nursed on the liver transplant unit, two were from adult oncology patients, two from patients on the renal transplant unit, one from a haematology patient and one from a patient initially nursed on the liver transplant unit but later transferred to an oncology ward. The epidemiological data associated with these bacteria are summarized in Table I .
Susceptibility testing
Antimicrobial susceptibility profiles were determined using a modified Stokes' method and the MICs of aztreonam, cefotaxime and ceftazidime were determined using the method of Holt & Brown.
14 All susceptibility tests were carried out using IsoSensitest agar (Oxoid, Basingstoke, UK). The -lactam antibiotics used for susceptibility testing were amoxycillin, amoxycillin ϩ clavulanic acid, ampicillin, aztreonam, carbenicillin, cefotaxime, cefsulodin, ceftazidime, cefoxitin, cefuroxime, cephradine, imipenem, piperacillin, piperacillin ϩ tazobactam, and temocillin. Other antibiotic susceptibilities tested include amikacin, chloramphenicol, ciprofloxacin, colistin sulphate, fosfomycin, gentamicin, nalidixic acid, rifampicin, streptomycin, sulphafurazole, tetracycline and trimethoprim. A screening method for identifying bacteria elaborating ESBLs was carried out using a disc synergy test.
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Analytical isoelectric focusing
This was performed as described by Heritage et al. 16 using brain heart infusion broth rather than LB broth.
Molecular methods
Plasmids were isolated using the method of Bennett et al. 17 E. coli DH5-␣ cells competent for transformation were prepared according to Hanahan. 18 Southern transfer and hybridization were carried out using the method of Southern.
19 Hybridization reactions were carried out using stringent annealing conditions at 68°C.
Pulsed field gel electrophoresis (PFGE) was performed as described by Barrett et al. 20 PCR amplification was used both to screen isolates for the presence of resistance genes by direct amplification and to prepare DNA probes to check the location of these genes. The genes that were sought belonged to the bla SHV-5 , bla TEM and bla AmpC families.
PCR amplifications were carried out as described by M'Zali et al. 21 except that for the bla AmpC -like gene the annealing temperature used was 62°C and 10% (v/v) dimethylsulphoxide was added to the reaction. The 861 bp TEM probe was prepared by PCR amplification of the bla TEM gene of plasmid pBR322 using primers 5Ј-AGGAAGAGTATGAGTAT-3Ј and 5Ј-TTACCAATGCTTAATCA-3Ј. A 631 bp fragment of the bla AmpC gene of C. freundii was isolated using primers 5Ј-ATAACCACCCAGTCACGC-3Ј and 5Ј-CAGTAGC- GAGACTGCGCA-3Ј. The 475 bp probe for the SHV gene was prepared in a similar manner using primer 5Ј-TCAGCGAAAAACACCTTG-3Ј and 5Ј-TCCCGCA-GATAAATCACCA-3Ј. Primer pairs used for PCR amplifications of the genes encoding SHV-and AmpC-type -lactamases were designed using the PRIMER design software on the VAX cluster at the University of Leeds. Those designed for the ampC gene were designed for the C. freundii enzyme. No attempt has been made to verify the use of these primers with chromosomal -lactamase genes other than of the Citrobacter type. The primers used to amplify the bla TEM gene were described by Hibbert-Rogers et al. 13 DNA probes were prepared by PCR amplification as described above except that the deoxynucleotide bases were replaced by PCR labelling mix (Boehringer Mannheim, Lewes, UK) and the product was purified using the Wizard PCR Preps purification system (Promega, Southampton, UK). Signal was detected using the DIG detection kit (Boehringer Mannheim).
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Restriction fragment length polymorphism (RFLP) analysis of the bla AmpC -like amplimer was carried out using PstI, HaeII and SauI (Boehringer Mannheim) according to the manufacturer's instructions. These enzymes were chosen using DNASIS (Hitachi Software Engineering, San Bruno, CA, USA) to identify restriction endonucleases capable of distinguishing published bla AmpC -like sequences.
The identity of the gene encoding the SHV -lactamase was determined using PCR-single-strand conformational polymorphism (PCR-SSCP) 21 and the nucleotide sequence of the TEM genes was determined using the dideoxy chain termination method of Sanger as described by HibbertRogers et al.
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Results
Susceptibility testing
All isolates were very mucoid when cultured on IsoSensitest agar (Oxoid Ltd, Basingstoke, UK). They were resistant to all of the antibiotics except imipenem. Eleven of the 16 isolates collected suggested the presence of an ESBL when the disc synergy test was used. Five isolates resistant to cefoxitin failed to exhibit synergy between clavulanic acid and either cefotaxime or ceftazidime. These five bacteria also failed to show synergy between piperacillin and tazobactam. There was a high level of resistance to cefotaxime and ceftazidime, as judged by the MICs of у 64 mg/L. These susceptibility data are summarized in Table II . Because of the resistance to counter-selective antibiotics, conjugal transfer of -lactam resistance into a laboratory strain of E. coli proved impossible, since no suitable recipient marker could be obtained. Attempts to transform competent E. coli DH5-␣ to extended-spectrum cephalosporin resistance were unsuccessful.
Plasmids
All 16 isolates reported in this study have plasmids that hybridize with the TEM probe. Often, more than one plasmid carries sequences that can bind this probe, suggesting that the gene encoding TEM -lactamase is present on more than one replicon in an individual isolate. Twelve isolates carried plasmid DNA that hybridized with the SHV probe; and all isolates also showed hybridization between this probe and the chromosomal DNA band. In five isolates, a plasmid of common size was found to hybridize to the bla AmpC probe. Two of these five isolates had very similar PFGE patterns even though they were isolated at different times and from patients on different units (Figure 1 ). Variations in their plasmid profiles support the hypothesis that they represent distinct isolates. 
␤-Lactamases
The identity of the TEM enzyme was determined by analytical isoelectric focusing and confirmed by nucleotide sequence analysis. All isolates carried genes encoding TEM-1A. 22 Similarly, isoelectric focusing suggested that the SHV enzyme was SHV-5. This was confirmed using PCR-SSCP (Figure 3) .
The five isolates carrying plasmids that hybridized with the bla AmpC probe were subjected to PCR amplification. All produced an amplimer of the size expected of a bla AmpC gene. Digestion with PstI, HaeII or SauI yielded an RFLP digestion pattern identical to that predicted from the nucleotide sequence of the BIL-1 -lactamase (Figure 4) . We thus conclude that -lactam resistance in these five isolates is due, at least in part, to the presence of a plasmidencoded AmpC-like enzyme and that this enzyme is probably BIL-1 or an as yet undescribed relative of this enzyme.
The first highly resistant isolate was collected in February 1994. This bacterium belonged to the group expressing the AmpC-type -lactamase. The patient was nursed on the renal unit. In July 1995, a second patient on the renal unit yielded another bacterium elaborating the AmpCtype -lactamase. The other three bacteria that produced this enzyme were isolated in March and April 1995 from patients nursed on the liver transplant unit and in November 1995 from a patient on an oncology ward. All patients who yielded cultures that produce the AmpC-type -lactamase had had close contact with people from the Indian subcontinent or had recently returned from there, where it is likely that they acquired these bacteria.
Discussion
This study develops earlier work which characterized the evolution and spread of a transposable TEM-derived ESBLs on the paediatric oncology unit of the same hospital. 13 The increasing occurrence of isolates expressing resistance to extended-spectrum cephalosporins poses a threat to the continued usefulness of these antibiotics. In the bacteria reported in this study, the resistance phenotype is complex. In most isolates high-level resistance to extended-spectrum cephalosporins is seen in bacteria that express two -lactamase genes: one ESBL (SHV-5) and one of narrower substrate specificity (TEM-1A). In five isolates within this set, resistance is augmented by the presence of a third gene, a bla AmpC -type gene that is plasmid located.
In four of the five isolates that produced the AmpC-type -lactamase, TEM-1A was present and one bacterium also produced a third -lactamase, SHV-5. With a single exception, all the bacteria that produced the SHV-5 ESBL were isolated from patients nursed on the liver transplant unit. This probably represents the local spread of a single large plasmid carrying the bla SHV-5 gene. In the latter part of this investigation, a patient nursed on a haematology ward yielded a bacterium that produced the SHV-5 ESBL. The SHV-5 resistance determinant was spreading through the hospital.
Chromosomal bla AmpC genes are species-or even strainspecific. The genetic basis of the mobilization of chromosomal bla AmpC -type genes on to plasmids has never been reported, with the exception of a report of Tn7-like associated sequences in a single strain producing MOX-1 isolated in Japan. 23 It is probable that mobilization of these genes occurs either by association with a transposable element(s) or as a result of the activity of integrons. 1, 16 It is crucial to understand the nature of this mobilization in order to ascertain the risk of further spread of a clinically significant resistance gene.
Although it has not proved possible to demonstrate the conjugal transfer of the plasmid encoding AmpC -lactamase in this instance, its presence on a plasmid significantly increases the chances that this resistance determinant will become more widely disseminated. In this study we have (c) also observed on the chromosome the occurrence of the bla SHV-5 gene that is normally located on plasmids. This suggests that previous attempts to classify -lactamases as chromosomal or plasmid-mediated are becoming meaningless.
The five highly resistant bacteria expressing the plasmidmediated AmpC-type -lactamase probably originated outside the UK, as four of the patients had recently returned from the Indian subcontinent and had received treatment whilst abroad. In the Indian subcontinent there are few controls over the prescription of antibiotics, creating conditions where intense selective pressures can exist. Such a situation has probably led to the selection of bacteria that are able to elaborate two or three separatelactamases, together conferring high-level resistance to all -lactams except for the carbapenems. The ease of global travel has made it easier for highly resistant strains to enter the UK. The potential for worldwide spread of bacteria that are resistant to one of the most useful and successful classes of antibiotic raises serious concerns for the continued effective use of these drugs, particularly for the treatment of life-threatening infections.
